
Internal Reference Number: FOI_9025
Date Request Received: 10/11/2025 00:00:00
Date Request Replied To: 26/11/2025 00:00:00
This response was sent via: By Email
Request Summary: treatment of myeloproliferative neoplasms
Request Category: Researcher
| Question Number 1: Please provide the total number of patients treated in the last 6 months for: • Polycythaemia Vera (ICD10 code D45) • Myelofibrosis (ICD10 code D47.4) • Myelofibrosis (ICD10 code D47.4) patients aged 65 and older | |
| Answer To Question 1: Please see our response to all questions in the spreadsheet attached. To accompany this answer to question 1 please also see the documents listed below: | |
| Question Number 2: How many patients were treated in the past 6 months (for any disease) with: • Ruxolitinib • Fedratinib • Momelotinib | |
| Answer To Question 2: Please see our response to all questions in the spreadsheet attached. | |
| Question Number 3: How many patients were treated with Ruxolitinib in the past 6 months for the following diseases? • Myelofibrosis (ICD10 code D47.4) • Polycythaemia Vera (ICD10 code D45) • Other/Unknown | |
| Answer To Question 3: Please see our response to all questions in the spreadsheet attached. | |
| Question Number 4: How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years? • Of these patients, how many were treated in the past 6 months with Hydroxycarbamide? • Of these patients, how many were treated in the past 6 months with Interferon therapy? • Of these patients, how many have received no active treatment in the past 6 months? | |
| Answer To Question 4: Please see our response to all questions in the spreadsheet attached. | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at 91Ó°ÊÓ District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.